

Investor Notes



Amanda
Cooper
medtechmanda.com

VOLUME 1 · ISSUE 3

Q3 2026

JUL. TO SEP. 2026

PUBLISHED OCTOBER 2026

MEDTECH M&A MONITOR

Sub-\$200M Transactions & Strategic Partnerships

Data note: All transactions listed are drawn from publicly available sources as of September 30, 2026. Deal values are stated where disclosed and may include assumed debt, contingent consideration, milestones, or customary purchase-price adjustments.

Undisclosed transactions are included where the target, structure, and strategic rationale appear relevant to the sub-\$200M medtech market; inclusion does not confirm a transaction value below the threshold. Axogen / BioCircuit is included at the \$200M boundary.

Larger transactions are included only as market context. Readers are encouraged to verify specific details before distribution or investment use.

Q3 2026 was a more selective quarter than Q2. Preliminary industry data indicates that healthcare M&A volume declined sequentially, with 391 transactions in the quarter versus 564 in the comparable prior-year period. But medtech activity remained strategically active — particularly in peripheral nerve repair, orthopedics, bone regeneration, medical device manufacturing, and cardiac asset carve-outs. The transactions of the quarter cluster around a single organising idea: acquirers, both strategic and PE-backed, are buying discrete capabilities to strengthen platforms they already own.

Q3 2026: Bolt-ons, carve-outs, and capability ownership.

8

M&A TRANSACTIONS COVERED

<\$200M

PER-DEAL VALUE THRESHOLD

4

STRATEGIC PARTNERSHIPS

1

NOTABLE STRATEGIC DIVESTITURE

7

INVESTOR TAKEAWAYS

I SECTION ONE
Sub-\$200M M&A Transactions · Q3 2026

DePuy Synthes → Expanding Innovations

ACQUIRER

DePuy Synthes / Johnson & Johnson MedTech

Global orthopedics franchise within J&J MedTech, with major businesses in trauma, spine, joint reconstruction, sports medicine, and surgical robotics (VELYS).

TARGET

Expanding Innovations

Developer of expandable interbody technology for spinal fusion procedures. The technology allows surgeons to adjust implant height and positioning intraoperatively, addressing fit variability across spinal anatomy.

DEAL VALUE: UNDISCLOSED · STRATEGIC TUCK-IN ACQUISITION · EXPANDABLE INTERBODY ADDITION TO J&J SPINE AND ROBOTICS PORTFOLIO

DePuy Synthes acquired Expanding Innovations in July, adding expandable interbody technology to its spine portfolio and linking the asset to the company's broader robotics strategy. The transaction follows a familiar large-strategic pattern: acquire a focused technology that complements an existing procedural ecosystem rather than buy a standalone company at scale. Expandable interbody devices sit at the intersection of implant design, procedural efficiency, and robotic planning — precisely the intersection where large orthopedic strategies are now competing.

WHY IT'S INTERESTING

The acquisition suggests spine strategics are increasingly interested in technologies that integrate with navigation and robotics rather than evaluated purely as implants. For investors, the important question is not simply whether an implant has clinical differentiation, it is whether the product becomes part of a broader workflow involving preoperative planning, navigation, robotics, and intraoperative decision support. That integration can make a small device company strategically valuable well below the revenue thresholds that would matter for a standalone exit. The signal for founders in adjacent spine categories: build for platform integration from the beginning, not as an afterthought.

Isto Biologics → NovaBone

ACQUIRER

Isto Biologics

Keensight Capital-backed company focused on bone healing and bone graft substitutes. Keensight invested in Isto approximately ten months prior to this transaction.

TARGET

NovaBone Products

Alachua, Florida-based developer and manufacturer of synthetic bone graft products based on proprietary bioactive glass technology. Products used in spine, orthopedics, trauma, foot and ankle, extremities, and dental procedures. Sold in more than 40 countries; more than two decades of clinical evidence. Divested from Halma plc.

DEAL VALUE: UNDISCLOSED · PE-BACKED PLATFORM ACQUISITION · DIVESTED FROM HALMA PLC · ADDS INTERNATIONAL DISTRIBUTION, CLINICAL EVIDENCE BASE, AND COMPLEMENTARY MANUFACTURING / R&D

Isto acquired NovaBone from Halma plc approximately ten months after Keensight Capital's investment in Isto — a compressed post-close deployment timeline that speaks to how quickly PE-backed medtech platforms are moving on identified targets. NovaBone adds a differentiated synthetic bone graft portfolio, an established international presence, complementary manufacturing and R&D capabilities, and a clinical evidence base built over two decades. For Isto, the transaction converts a single-product bone healing company into a broader bone-graft substitute platform. For NovaBone, it moves the asset from a diversified conglomerate parent (Halma) to a specialist owner whose entire commercial focus is bone healing.

WHY IT'S INTERESTING

This is a classic private-equity platform add-on and a case study in the recurring medtech pattern of corporate parent divesting a focused asset to a specialist PE-backed platform that becomes the more natural long-term owner. Bone graft substitutes are particularly attractive for this style of consolidation because the products sell through overlapping orthopedic, spine, trauma, and dental channels — clinical categories with substantial rep-density overlap. For investors: the deal reinforces the value of identifying companies with strong clinical histories but insufficient commercial scale to justify a strategic exit. A PE platform can acquire the asset, fold it into a purpose-built commercial infrastructure, and generate exit value that the standalone company could not have accessed on its own.

Stryker → ZuriMED

ACQUIRER

Stryker (NYSE: SYK)

Global medical technology company with substantial businesses in orthopedics, surgical equipment, neurovascular intervention, and medical robotics. Continues to build its sports medicine and shoulder franchise.

TARGET

ZuriMED Technologies

Zurich-based developer of the FiberLocker System, a soft-tissue augmentation technology intended to address failure and healing challenges in rotator cuff repair. Focused single-product company with existing commercial and strategic interest from Stryker prior to the transaction.

DEAL VALUE: UNDISCLOSED · STRATEGIC TUCK-IN ACQUISITION · SHOULDER AND SPORTS MEDICINE PORTFOLIO ADDITION

Stryker agreed to acquire ZuriMED after developing a commercial and strategic interest in the FiberLocker System. The technology adds a differentiated soft-tissue repair capability to Stryker's shoulder portfolio and complements its broader sports medicine and orthopedic reconstruction businesses. Rotator cuff repair remains a category where reoperation and failure rates create meaningful clinical and economic opportunity for augmentation technologies that improve healing outcomes — the exact opportunity FiberLocker is designed to address.

WHY IT'S INTERESTING

The transaction reinforces the strategic importance of shoulder repair as a category where large orthopedic companies are competing across implants, anchors, biologic augmentation, and procedural tools. Stryker's acquisition of a relatively focused Swiss company signals that differentiated soft-tissue technologies can attract strategic interest without requiring broad commercial scale. For founders, the pattern is clear: a device designed to improve the success rate or healing profile of an established orthopedic procedure may be more attractive than a product that merely adds another implant option to a saturated category. Strategic buyers are prioritising technologies that improve the outcome of a large existing procedure category over technologies that expand the SKU count within one.

Axogen → BioCircuit Technologies

ACQUIRER

Axogen, Inc. (Nasdaq: AXGN)

Specialty medical technology company focused on surgical solutions for the restoration of peripheral nerve function. Existing portfolio spans nerve grafts, conduits, and repair technologies.

TARGET

BioCircuit Technologies

Developer of NerveTape, described as the first FDA-approved device for sutureless peripheral nerve repair. NerveTape aligns, connects, and protects transected nerves without relying on traditional microsutures.

DEAL VALUE: \$200M CASH AT CLOSING, SUBJECT TO CUSTOMARY ADJUSTMENTS · EXPECTED CLOSE Q4 2026 · EXACTLY AT THE NEWSLETTER'S \$200M THRESHOLD · EXPECTED TO BE ACCRETIVE TO REVENUE GROWTH, GROSS MARGIN, ADJUSTED EBITDA MARGIN, AND ADJUSTED EPS AFTER CLOSING

Axogen entered into a definitive agreement to acquire BioCircuit for \$200M in cash. The transaction adds NerveTape to Axogen's existing portfolio of nerve grafts, conduits, and repair technologies. Axogen expects the acquisition to contribute to 2027 revenue and to be accretive across every relevant financial metric after closing. The combination creates a more complete peripheral nerve repair platform: Axogen's existing products primarily support nerve regeneration and repair, while NerveTape addresses the mechanical connection and protection step in the surgical procedure. The two product classes are complementary rather than overlapping.

WHY IT'S INTERESTING

The transaction shows how a specialised strategic acquirer can justify a premium for a product that appears narrow in isolation. Axogen already has the surgeon relationships, training infrastructure, and commercial focus required to make NerveTape part of a broader nerve-repair workflow — the kind of infrastructure a standalone BioCircuit would have needed years and considerable capital to build. This is the case study of the quarter for the "acquire the missing capability" thesis. For founders in adjacent nerve categories (monitoring, stimulation, regeneration): the acquirer universe is now defined enough to plan against, and the price point Axogen paid provides a public reference for FDA-cleared peripheral nerve technology. The deal sits exactly at this newsletter's \$200M threshold and is included on the boundary; it is the largest transaction we profile this quarter.

Jaguar LAA ← Johnson & Johnson (Laminar Assets)

ACQUIRER / NEWCO

Jaguar LAA, Inc.

Newly formed private medical device company established with Santé Ventures and members of the Laminar management team. Structured to take responsibility for the next stage of Laminar's clinical and regulatory development.

SELLER

Johnson & Johnson (NYSE: JNJ)

Acquired Laminar in 2023 for approximately \$400M. The Laminar program is focused on catheter-based left atrial appendage closure for patients with non-valvular atrial fibrillation, using a rotational approach intended to close and eliminate the appendage while minimising device exposure within the left atrium.

DEAL VALUE: UNDISCLOSED · ASSET ACQUISITION AND MANAGEMENT-LED NEWCO FORMATION · DEVELOPMENT-STAGE CARDIOVASCULAR TECHNOLOGY · FOLLOWS SUSPENSION OF LAMINAR'S PIVOTAL STUDY IN 2025 OVER DEVICE UNWRAPPING AND CLINICALLY SIGNIFICANT LEAK CONCERNS

Jaguar LAA acquired assets associated with J&J's Laminar program, including key intellectual property, development assets, and members of the team responsible for the technology. J&J had acquired Laminar in 2023 for approximately \$400M; the Q3 2026 divestiture follows the suspension of Laminar's pivotal study in 2025 over concerns involving device unwrapping and clinically significant leaks. This is not a technology being abandoned. A new company formed around the program, backed by Santé Ventures and members of the original management team, is taking responsibility for a reset of the clinical and regulatory plan under focused ownership.

WHY IT'S INTERESTING

This is one of the most instructive transactions of the quarter despite its undisclosed value. It is a portfolio-reversal deal: J&J exiting an asset it bought for approximately \$400M, while a management-backed company with venture sponsorship takes responsibility for what comes next. Divestiture does not necessarily signal technological failure. Large strategics may sell assets because a program no longer fits capital-allocation priorities, internal risk tolerance, or portfolio focus — not because the underlying technology is dead. A smaller, dedicated owner with specialist capital may be willing to pursue a narrower clinical and regulatory strategy that the strategic could not justify. For investors, the transaction provides a template for distressed or non-core medtech assets: form a new company around the technology, retain the operating team, secure specialist capital, and reset the development

plan. Expect more of these as the 2021 – 2023 vintage of strategic medtech acquisitions matures and gets reassessed against current portfolio priorities.

SEPTEMBER 2026

CDMO PLATFORM ADD-ON

MEDICAL DEVICE MANUFACTURING / COSTA RICA

Command Medical Products → IMATS

ACQUIRER

Command Medical Products

Argosy Capital-backed contract manufacturer serving medical device customers across catheter, single-use, and disposable device categories.

TARGET

Injection Moulding & Tooling Services (IMATS)

Costa Rica-based provider of injection molding and tooling services for medical device manufacturing. Establishes Command Medical's third manufacturing site and adds precision tooling and injection-molding capabilities to its platform.

DEAL VALUE: UNDISCLOSED · MANUFACTURING PLATFORM ADD-ON · THIRD COMMAND SITE
· COSTA RICA NEARSHORING FOOTPRINT

Command Medical acquired IMATS to expand its medical device manufacturing capabilities and establish a third manufacturing site in Costa Rica. The transaction extends Command's presence across the medical device value chain and adds tooling and injection-molding capabilities to an existing catheter and disposable device manufacturing platform. A Costa Rican site also carries direct nearshoring and supply-chain resilience benefits for North American OEM customers navigating tariff exposure and logistics uncertainty.

WHY IT'S INTERESTING

Manufacturing M&A continues to be an important but under-covered part of medtech consolidation. The value of these transactions is not in a single device or regulatory approval; it is in capacity, process expertise, customer relationships, geographic redundancy, and the switching costs that a validated manufacturing partner creates for its OEM customers. For investors, CDMO platforms with validated quality systems, established OEM relationships, and cross-site capability continue to be attractive acquisition targets even when the underlying manufacturing processes are not headline technologies. The category is also insulated from the specific-product regulatory and clinical risks that dominate device investing — one of its most durable long-run attractions.

Precera Medical → Additive Metal Services

ACQUIRER

Precera Medical

SK Capital-backed medical device contract development and manufacturing platform launched in November 2025. Actively assembling capability across the design-to-commercial-production continuum.

TARGET

Additive Metal Services

Port Huron, Michigan-based provider of metal injection molding and sinter-based additive manufacturing for medical device customers. Adds precision metal component capability to Precera's existing design, machining, prototyping, and assembly platform.

DEAL VALUE: UNDISCLOSED · PLATFORM ACQUISITION · ADDS MIM AND SINTER-BASED ADDITIVE MANUFACTURING TO A NEWLY LAUNCHED CDMO PLATFORM

Precera acquired the assets and business of Additive Metal Services to expand from design, machining, prototyping, and assembly into more complex precision metal components. The company intends to support customers from early development through automated production — a full-lifecycle CDMO proposition that is difficult to replicate through vendor coordination. The transaction is the second visible PE-backed CDMO consolidation of the quarter, alongside Command Medical / IMATS.

WHY IT'S INTERESTING

The transaction shows PE-backed CDMO platforms assembling complementary manufacturing capabilities rather than acquiring finished-device brands. The strategic value lies in becoming difficult for OEM customers to replace across the product-development lifecycle. For emerging device companies, a vertically integrated manufacturing partner reduces the number of vendor handoffs between prototype, process validation, and commercial production — one of the persistent execution risks in early commercial-stage device companies. For investors, the diligence question is whether the platform is simply adding equipment or genuinely building a differentiated, quality-system-integrated manufacturing network. The two are frequently confused in CDMO pitch decks.

Cyrix Healthcare → Blue Star E&E MedTech Solutions

ACQUIRER

Cyrix Healthcare

Somerset Indus Capital Partners-backed healthcare technology platform focused on medical equipment sales, installation, maintenance, refurbishment, and lifecycle management across India, West Asia, and Africa.

TARGET / BUSINESS UNIT

Blue Star E&E MedTech Solutions

Multi-brand CT and MRI sales, installation, service, and support business acquired from Blue Star Engineering & Electronics. More than 250 installations and an experienced field service team transferring to Cyrix.

DEAL VALUE: UNDISCLOSED · EFFECTIVE SEPTEMBER 1, 2026 · MEDICAL IMAGING LIFECYCLE MANAGEMENT PLATFORM EXPANSION

Cyrix acquired Blue Star E&E's MedTech Solutions business to expand its imaging capabilities across India, West Asia, and Africa. The transaction strengthens Cyrix's "total medtech management" model by combining equipment sales with installation, maintenance, repairs, refurbishment, and lifecycle services. The acquired business brings more than 250 installations and an experienced field service team into Cyrix's platform, meaningfully extending the addressable customer base for its recurring-revenue service model.

WHY IT'S INTERESTING

The deal illustrates the emergence of medical equipment lifecycle management as an investable medtech services category — distinct from device manufacturing and distinct from clinical device commercialisation. The value proposition is not selling imaging equipment; it is helping hospitals manage complex, mixed-brand fleets throughout their useful life. The model is especially relevant in markets where hospitals operate equipment from multiple OEMs and where refurbishment economics are more favourable than full replacement cycles. Independent service and refurbishment platforms create recurring revenue, improve equipment utilisation, and provide a lower-cost alternative to OEM-managed service contracts — a triangulation that has been quietly attractive to healthcare-focused PE for several years.

Undisclosed and Smaller Transactions of Note

P&F Products & Features → AVVie GmbH (Aug. 5, 2026) — Undisclosed acquisition in the medical device sector; limited public detail on strategic rationale.

Johnson & Johnson MedTech → Atraverse Medical (Q3 2026) — Undisclosed acquisition adding left-heart access technology to J&J's cardiac ablation portfolio. Notable in the same quarter J&J divested Laminar assets to Jaguar LAA: an active rebalance across cardiac subcategories, not a category exit.

Leica Biosystems → StatLab Medical Products (Q3 2026) — Undisclosed acquisition; diagnostics and pathology consumables add-on strengthening Danaher's pathology portfolio.

Q3 2026 · MARKET CONTEXT

The Larger Deals Framing This Quarter

Five Q3 transactions exceeded the newsletter's sub-\$200M threshold and are included as context because each illuminates strategic priorities in adjacent categories.

Medtronic acquired SPR Therapeutics at reported total consideration of approximately \$650M, adding the SPRINT Peripheral Nerve Stimulation System — a minimally invasive platform for temporary peripheral nerve stimulation in acute and chronic pain. The transaction expands the peripheral nerve category from Axogen's repair-focused positioning into temporary neuromodulation, and provides a strong strategic marker for non-opioid pain management. Together with Axogen / BioCircuit, it is the clearest signal that peripheral nerves are becoming a defined medtech category, not a scattered set of adjacent technologies. **MiMedx agreed to acquire Sanara MedTech** at an approximate \$350M enterprise value in cash and stock, expanding MiMedx's surgical footprint and diversifying beyond traditional wound care — a demonstration that biologics, advanced wound care, and surgical products continue to converge into a single addressable market. **ResMed acquired Noctrix Health** for approximately \$340M, adding a neuromodulation platform for restless legs syndrome and further extending the non-opioid, non-implant pain and sleep therapeutic category. **Olympus acquired BioProtect** at approximately \$270M, adding prostate cancer care technology to its urology and oncology portfolio. **Cornerstone Robotics announced a strategic partnership with Medtronic** involving a reported \$700M investment and distribution rights for the Sentire surgical system in selected markets outside the United States — structurally a partnership, functionally a scale-up path for Cornerstone without an immediate acquisition. It appears in this market-context section rather than the partnerships section for that reason.

Collectively, these larger transactions reinforce the sub-\$200M tier's story rather than compete with it. Strategics are buying discrete capabilities across pain, wound care, urology, and surgical robotics — the same bolt-on architecture visible below the threshold, executed at scale.

II SECTION TWO Strategic Partnerships · Non-M&A Activity Q3 2026

Abbott × Google Health

Q3 2026 · CONSUMER METABOLIC HEALTH · GLUCOSE DATA + AI-ENABLED PATIENT ENGAGEMENT

Abbott and Google Health announced a multi-year partnership combining data from Abbott's Lingo glucose biowearable with Google's consumer technology and AI capabilities. The intended result is a more unified metabolic-health experience within the Google Health ecosystem, integrating continuous glucose data with the daily surfaces (search, health apps, Fitbit) where consumers already live.

The partnership reflects a broader shift in wearable strategy: device companies are increasingly seeking consumer software, AI, and engagement partners rather than building the entire digital layer independently. For investors, the relevance is that the strategic value of a biosensor may increasingly depend on its ability to generate actionable insights within a broader consumer or clinical platform — not on the sensor's technical specifications alone. Standalone biosensor economics are getting harder; platform-integrated biosensor economics are getting more interesting.

Clarius Mobile Health × Inteleos

Q3 2026 · POINT-OF-CARE ULTRASOUND · HARDWARE + CERTIFICATION BUNDLE

Clarius Mobile Health partnered with Inteleos' Point-of-Care Ultrasound Certification Academy to pair Clarius portable ultrasound systems with access to structured POCUS education and certification. The partnership is not a conventional distribution arrangement; it is a commercialisation partnership designed to remove an adoption barrier.

Point-of-care ultrasound has a persistent adoption gap: clinicians acquire devices but lack confidence performing and interpreting scans, which suppresses utilisation and increases return rates. Linking hardware with structured certification addresses that friction directly and creates a mechanism for improved retention. The pattern is worth watching in other diagnostic categories where clinical confidence — not device capability — is the actual constraint on adoption. Handheld ultrasound, handheld ECG, wearable cardiac monitors, and portable POC diagnostics all share this profile.

Accuray × Samsung NeuroLogica

Q3 2026 · RADIATION ONCOLOGY · MOBILE CT + IMAGE GUIDANCE FOR CYBERKNIFE

Accuray and Samsung NeuroLogica entered into agreements to pursue advanced volumetric imaging capabilities for the CyberKnife System. Samsung contributes mobile CT expertise; Accuray contributes precision treatment delivery and motion-management capabilities. The intent is enhanced targeting, planning, and treatment verification without replacing the underlying treatment system.

The collaboration reflects a growing trend toward modular oncology platforms. Rather than replacing the treatment system, advanced imaging enhances targeting, planning, and treatment verification. The broader strategic implication: imaging and therapy companies are increasingly partnering in configurations where neither party independently controls the entire clinical workflow. That model creates a cleaner market for capability providers in image guidance, motion management, adaptive planning, and treatment verification — all of which can plug into multiple therapy platforms without single-vendor lock-in.

PDV MedTech × Corscience

JUL. 7, 2026 · U.S. MANUFACTURER + EUROPEAN DEVELOPER · CROSS-ATLANTIC DEVELOPMENT-TO-MANUFACTURING PIPELINE

PDV MedTech (INDO-MIM company), a U.S.-based medical device design, development, and manufacturing organisation, and Corscience GmbH, a Germany-based developer of safety-critical medical technologies, announced a strategic partnership creating an end-to-end path from development through commercialisation across Europe and the United States. The alliance combines Corscience's engineering expertise in complex medical devices with PDV MedTech's manufacturing infrastructure spanning California, Utah, Texas, Mexico, India, and the UK. European innovators gain access to PDV's U.S. and global manufacturing capabilities; U.S. companies gain Corscience's EU MDR regulatory expertise and European development infrastructure. Announced early in the quarter (July 7); included here rather than in Q2 to reflect the calendar-quarter cutoff.

The partnership addresses a persistent challenge for cross-Atlantic medtech development: proximity to specialised engineering teams, EU MDR regulatory readiness, and access to scalable manufacturing typically require separate vendor relationships and complex coordination. The combined operating model removes that friction. Timing matters — EU MDR transition pressure has continued to create demand for regulatory-sophisticated European development partners, and nearshoring and supply-chain resilience concerns are driving U.S. medtech companies to diversify their manufacturing footprints. The partnership is the third distinct Q3 signal (alongside Command / IMATS and Precera / Additive Metal Services) that manufacturing capability is being reorganised as a first-class medtech strategic asset, not a back-office function.

III SECTION THREE

Q3 2026 Themes · What the Quarter Signalled

Bolt-ons remained the dominant architecture.

Stryker's ZuriMED acquisition, Axogen's BioCircuit agreement, Isto's NovaBone add-on, and Command Medical's IMATS purchase each addressed a specific capability or channel gap in an existing platform. This is consistent with the broader 2026 medtech market. Industry commentary has characterised the year as a return of the bolt-on: strategics and PE-backed platforms are fortifying existing categories one technology at a time rather than relying on transformative acquisitions.

Portfolio ownership is becoming more conditional.

The Jaguar LAA transaction provides the clearest Q3 example of conditional strategic ownership. J&J's decision to sell Laminar after suspending its pivotal study shows that even a major strategic owner may exit a development-stage asset when risk, capital allocation, or portfolio priorities change. But the asset was not abandoned — a new company formed around the program, backed by Santé Ventures and members of the original management team, is taking responsibility for further development. This creates a more differentiated exit environment: assets may move from a strategic owner to a specialist owner without disappearing from the market.

Manufacturing became a more visible M&A category.

Precera / Additive Metal Services and Command Medical / IMATS highlight the continuing consolidation of medical device manufacturing capabilities. Both transactions add process expertise, capacity, and geographic reach rather than branded finished devices. The activity is strategically important because OEMs increasingly value supply-chain resilience, validated production processes, and the ability to move a device from development through automated manufacturing. The manufacturing partner is becoming part of the medtech product strategy, not merely a back-office supplier.

Peripheral nerve technologies are forming a defined category.

Axogen's acquisition of BioCircuit and Medtronic's acquisition of SPR Therapeutics point to broadening strategic interest in peripheral nerve technologies. The transactions address different stages of care — nerve repair and neuromodulation — but share a focus on restoring or modulating peripheral nerve function. The category may become increasingly attractive because it spans trauma, reconstructive surgery, chronic pain, and rehabilitation. Companies with products that can be integrated into a broader nerve-care platform may receive more strategic attention than companies selling isolated point solutions.

IV SECTION FOUR Takeaways for Medtech Investors

01 The bolt-on has become the default strategic language

Q3's most relevant transactions were focused acquisitions designed to add one missing capability: FiberLocker for shoulder repair, NerveTape for peripheral nerve repair, NovaBone for bone graft substitutes, additive manufacturing for a CDMO platform. For investors, the implication is that exit analysis should begin with the question: *which larger platform can use this asset immediately?* A company does not need to be independently comprehensive if its technology fills a clearly defined gap in a scaled commercial system. That reframing changes both target-buyer identification and the appropriate valuation framework at exit.

02 Peripheral nerve repair is becoming an investable medtech lane

Axogen's \$200M BioCircuit acquisition provides a direct valuation marker for FDA-approved peripheral nerve repair technology. NerveTape extends Axogen's portfolio from biological nerve regeneration into the mechanical connection and protection phase of repair. The broader market signal comes from Medtronic's SPR acquisition (approximately \$650M), which expands the peripheral nerve opportunity into temporary neuromodulation and chronic pain. Investors should distinguish between nerve repair, nerve stimulation, nerve monitoring, and nerve regeneration, but the category now has enough strategic activity to justify dedicated coverage in a way it did not eighteen months ago.

03 Manufacturing assets can offer more predictable platform value than early-stage devices

Precera and Command Medical acquired process capabilities that serve multiple OEM customers and product categories. These assets generate value through recurring manufacturing revenue, customer switching costs, validated quality systems, and geographic diversification. For private equity investors, manufacturing platforms support buy-and-build strategies with clearer integration logic than a collection of unrelated device brands. Diligence should focus on customer concentration, validation status, margin expansion runway, capacity utilisation, and the ability to transfer production between sites without regulatory re-work.

04 Strategic divestitures can create second-life opportunities

The Laminar transaction demonstrates that an asset sold by a large strategic may still have meaningful development value under a dedicated owner. J&J's prior \$400M acquisition price is not a reliable indicator of current value, but it establishes the magnitude of capital that had previously been committed to the program. For investors, the opportunity lies in identifying assets where the strategic owner's problem is portfolio fit rather than fundamental impossibility. The most attractive carve-outs may include technology, clinical data, regulatory work, and an experienced team — an underappreciated combination that is difficult to reassemble from scratch. Expect more of these as the 2021 – 2023 medtech acquisition vintage gets reassessed against current strategic priorities.

05 Orthopedic M&A is expanding from implants to procedure outcomes

Stryker's acquisition of ZuriMED and Zimmer Biomet's prior iovera[®] transaction (Q2 2026) show that orthopedic strategies are broadening their focus beyond implants. Soft-tissue augmentation, perioperative pain, biologics, surgical workflow, and rehabilitation technologies can all strengthen the economics of the underlying procedure. This suggests a more expansive definition of orthopedic strategic fit. Companies should position their products around improved procedure success, reduced complications, faster recovery, or better outpatient economics rather than describing themselves only by device category — a repositioning that meaningfully expands the acquirer universe.

06 The distribution relationship remains an acquisition test

The Q2 Spectrum Vascular / Piccolo transaction established the distribution-to-acquisition pattern; Q3 activity reinforced its importance through multiple strategic partnerships that combine hardware with education, software, or geographic distribution. For emerging companies, the right commercial partner can serve as a live-market validation mechanism. A distribution partner that invests in training, implementation, and customer access may become a logical acquirer if the product proves commercially useful — and the terms of the distribution agreement should be structured with that eventual conversation in mind.

07 Revenue quality matters more than headline revenue

Several Q3 transactions involve businesses whose strategic value extends beyond current revenue. NovaBone contributes clinical evidence and international distribution; IMATS contributes manufacturing capabilities; BioCircuit contributes a differentiated FDA-approved product; Laminar contributes a development program and specialist team. Investors should evaluate strategic assets using a broader framework: regulatory position, clinical evidence, reimbursement or procedure economics, commercial-channel fit, manufacturing readiness, integration into an existing platform, and availability of specialised management talent. Any one of these can be the reason for an acquisition; revenue is often the last factor considered rather than the first.

Investor Notes is intended for informational purposes and does not constitute investment advice. All deal terms reflect publicly available disclosures as of September 30, 2026. Undisclosed transactions are included where target, structure, and strategic rationale appear relevant to the sub-\$200M medtech market; inclusion does not confirm a transaction value below the threshold. Axogen / BioCircuit is included at the \$200M boundary. Larger transactions are included only as market context. Visit medtechmnda.com for additional research.

A.E. COOPER MEDTECH VENTURES · INVESTOR NOTES · MEDTECH M&A MONITOR · Q3 2026 ·
VOL. 1 · NO. 3 · © 2026